Heartflow, Inc. Announces Pricing of Upsized Initial Public Offering
Heartflow (NASDAQ: HTFL), an AI technology company focused on coronary artery disease (CAD), has announced the pricing of its upsized IPO. The company is offering 16,666,667 shares at $19.00 per share, expecting to raise approximately $316.7 million in gross proceeds.
Trading will commence on August 8, 2025, on the Nasdaq Global Select Market. The underwriters have a 30-day option to purchase up to 2.5 million additional shares. The IPO is expected to close on August 11, 2025, with J.P. Morgan, Morgan Stanley, and Piper Sandler serving as joint book-running managers.
Heartflow (NASDAQ: HTFL), un'azienda tecnologica specializzata in intelligenza artificiale focalizzata sulla malattia coronarica (CAD), ha annunciato il prezzo della sua IPO ampliata. La società offre 16.666.667 azioni a 19,00 $ per azione, prevedendo di raccogliere circa 316,7 milioni di dollari di proventi lordi.
Le negoziazioni inizieranno il 8 agosto 2025 sul Nasdaq Global Select Market. Gli underwriter hanno un'opzione di 30 giorni per acquistare fino a 2,5 milioni di azioni aggiuntive. L'IPO dovrebbe concludersi l'11 agosto 2025, con J.P. Morgan, Morgan Stanley e Piper Sandler come gestori congiunti del libro ordini.
Heartflow (NASDAQ: HTFL), una empresa tecnológica de inteligencia artificial centrada en la enfermedad de la arteria coronaria (CAD), ha anunciado el precio de su oferta pública inicial (IPO) ampliada. La compañía ofrece 16.666.667 acciones a 19,00 dólares por acción, esperando recaudar aproximadamente 316,7 millones de dólares en ingresos brutos.
La negociación comenzará el 8 de agosto de 2025 en el Nasdaq Global Select Market. Los suscriptores tienen una opción de 30 días para comprar hasta 2,5 millones de acciones adicionales. Se espera que la IPO cierre el 11 de agosto de 2025, con J.P. Morgan, Morgan Stanley y Piper Sandler como gestores conjuntos del libro de órdenes.
Heartflow (NASDAQ: HTFL)는 관상동맥질환(CAD)에 중점을 둔 인공지능 기술 회사로, 증액된 기업공개(IPO) 가격을 발표했습니다. 회사는 16,666,667주를 주당 19.00달러에 제공하며, 총 약 3억 1,670만 달러의 자금을 조달할 것으로 예상합니다.
거래는 2025년 8월 8일 나스닥 글로벌 셀렉트 마켓에서 시작됩니다. 인수단은 30일간 추가로 250만 주까지 매입할 수 있는 옵션을 보유하고 있습니다. IPO는 2025년 8월 11일에 마감될 예정이며, J.P. Morgan, Morgan Stanley, Piper Sandler가 공동 주간사로 참여합니다.
Heartflow (NASDAQ : HTFL), une entreprise technologique spécialisée en intelligence artificielle axée sur la maladie coronarienne (CAD), a annoncé le prix de son introduction en bourse élargie. La société propose 16 666 667 actions au prix de 19,00 $ par action, espérant lever environ 316,7 millions de dollars de produit brut.
Les négociations débuteront le 8 août 2025 sur le Nasdaq Global Select Market. Les souscripteurs disposent d'une option de 30 jours pour acheter jusqu'à 2,5 millions d'actions supplémentaires. L'introduction en bourse devrait se clôturer le 11 août 2025, avec J.P. Morgan, Morgan Stanley et Piper Sandler en tant que gestionnaires conjoints du livre d'ordres.
Heartflow (NASDAQ: HTFL), ein auf koronare Herzkrankheit (CAD) spezialisiertes KI-Technologieunternehmen, hat die Preisfestsetzung seines erweiterten Börsengangs bekanntgegeben. Das Unternehmen bietet 16.666.667 Aktien zu je 19,00 US-Dollar an und erwartet, etwa 316,7 Millionen US-Dollar Bruttoerlös zu erzielen.
Der Handel beginnt am 8. August 2025 am Nasdaq Global Select Market. Die Underwriter haben eine 30-tägige Option, bis zu 2,5 Millionen zusätzliche Aktien zu kaufen. Der Börsengang soll am 11. August 2025 abgeschlossen sein, wobei J.P. Morgan, Morgan Stanley und Piper Sandler als gemeinsame Bookrunner fungieren.
- None.
- 100% of shares offered are primary shares, indicating potential dilution for existing shareholders
- Additional dilution possible through 2.5M share underwriter option
Insights
Heartflow's upsized $316.7M IPO demonstrates strong investor appetite for AI-powered cardiac diagnostic technologies.
Heartflow's successful IPO represents a significant milestone for AI-based cardiovascular diagnostics. The company priced its offering at
The strong institutional backing is evident from the caliber of underwriters, with J.P. Morgan, Morgan Stanley, and Piper Sandler serving as joint book-running managers. This level of support typically indicates confidence in the company's business model and growth prospects.
Heartflow specializes in AI technology for coronary artery disease (CAD), positioning it at the intersection of two high-growth sectors: artificial intelligence and cardiovascular care. CAD remains one of the leading causes of mortality worldwide, creating substantial market opportunity. The company's AI solutions likely aim to improve diagnostic accuracy, reduce unnecessary invasive procedures, and potentially lower healthcare costs associated with CAD management.
The
MOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its upsized initial public offering of 16,666,667 shares of its common stock at a public offering price of
J.P. Morgan, Morgan Stanley and Piper Sandler are acting as joint book-running managers for the offering. Stifel and Canaccord Genuity are acting as co-managers for the offering.
A registration statement on Form S-1, including a prospectus, relating to these securities was declared effective by the U.S. Securities and Exchange Commission on August 7, 2025. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from J.P. Morgan, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at prospectus@morganstanley.com; or Piper Sandler & Co., 350 North 5th Street, Suite 1300, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at 800-747-3924 or by email at prospectus@psc.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Heartflow, Inc.
Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform — including Roadmap™ Analysis, FFRCT Analysis and Plaque Analysis — is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. Heartflow has helped clinicians manage over 400,000 patients worldwide.
Media Contact
Elliot Levy
elevy@heartflow.com
Investor Contact
Nick Laudico
nlaudico@heartflow.com
